Floating granules of ranitidine hydrochloride-gelucire 43/01: Formulation optimization using factorial design

AAPS PharmSciTech

Volumn 8, Issue 2, 2007, Pages

  Patel, Dasharath M ^a   Patel, Natavarlal M ^a   Patel, Viral F ^a   Bhatt, Darshini A ^a  

^a Shri B M Shah College of Pharmacy Modasa   (India)

Author keywords

Floating; Gelucire; Multiunit lipid granules; Ranitidine hydrochloride

Indexed keywords

DRUG CARRIER; ETHYL CELLULOSE; GELUCIRE; GLYCEROL BEHENATE; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE; RANITIDINE; GELUCIRE 43 01; GELUCIRE 43-01; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG GRANULATION; DRUG SCREENING; DRUG SOLUBILITY; FACTORIAL DESIGN; HUMIDITY; HYDROPHOBICITY; IN VITRO STUDY; MELTING POINT; PREDICTION; PROCESS OPTIMIZATION; REGRESSION ANALYSIS; TEMPERATURE SENSITIVITY; CHEMISTRY; DRUG STABILITY; METHODOLOGY; TEMPERATURE;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; RANITIDINE; REGRESSION ANALYSIS; TEMPERATURE; TRIGLYCERIDES;

EID: 34247578171     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0802030     Document Type: Article

References (27)

1. Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. Air compartment multiple-unit system for prolonged gastric residence, Part I: formulation study. Int J Pharm. 1998;174:47-54.
2. Santus G, Lazzarini G, Bottoni G, et al. An in vitro-in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm. 1997;44:39-52.
3. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm. 1996;22:531-539.
4. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997;14:815-819.
5. Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci. 1994;83:239-245.
6. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention.J Control Release 1998;55:3-12.
7. Park K, Park H. Enzyme digestible balloon hydrogel for long term oral drug delivery: synthesis and characterization. Int Symp Rel Bioact Mater. 1987;14:41-42.
8. Ch'Ng HS, Park H, Kelly P, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery, II: synthesis and evaluation of some swelling water-insoluble bioadhesive polymers. J Pharm Sci. 1985;74:399-405.
9. Kaniwa N, Aoyagi N, Ogata H, Ejima A. Gastric emptying of enteric coated drug preparations, II: effect of size and density of enteric coated drug preparations and food on gastric emptying rates in humans. J Pharmacobiodyn. 1988;11:571-575.
10. Efentakis M, Koutlis A, Vlachou M. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS PharmSciTech. 2000;1:E34.
11. Dennis AB, Farr SJ, Kellaway IW, Taylor G, Davidson R. In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. Int J Pharm. 1990;65:85-100.
12. Remunan C, Bretal M, Nunez A, Bila Jato JL. Accelerated stability of sustained release tablet prepared with Gelucire. Int J Pharm. 1992;80:151-159.
13. Saraiya D, Bolton D. The use of Precirol to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev Ind Pharm. 1990;16:1963-1969.
14. Li S, Lin S, Chien YW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2001;2:E1.
15. Kumar MK, Shah MH, Ketkar A, Mahadik KR, Paradkar A. Effect of drug solubility and different excipients on floating behavior and release from glyceryl monooleate matrices. Int J Pharm. 2004;272:151-160.
16. Aïnaoui A, Vergnaud JM. Modelling the plasma drug level with oral controlled release forms with lipidic Gelucire. Int J Pharm. 1998;169:155-162.
17. Sheu MT, Hsia AHO. Polyglycolized saturated glycerides as carrier and enhancer for drug penetration. Chin Pharm J. 2001;53: 107-111.
18. Barker SA, Yap SP, Yuen KH, McCoy CP, Murphy JR, Craig DQM. An investigation into the structure and bioavailability of a-tocopherol dispersion in Gelucire 44/14. J Control Release. 2003;91:477-488.
19. Sutananta W, Craig DQM, Newton JM. An evaluation of the mechanisms of drug release from glyceride bases. J Pharm Pharmacol. 1995;47:182-187.
20. Shimpi S, Chauhan B, Mahadik KR, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech. 2004;5:E43.
21. Flynn M. Histamine H2 antagonists. In: Hagemann RC, Threlkeld DS, eds. Drug Facts and Comparisons. 50th ed. St Louis, MO: Wolters Kluwer Co; 1996:1862-1876.
22. Somade S, Singh K. Comparative evaluation of wet granulation and direct compression methods for preparation of controlled release ranitidine HCL tablets. Indian J Pharm Sci. 2002;64:285.
23. Lauritsen K. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases. Clin Pharmacokinet. 1990;19:11-31, 94-125.
24. Grant S. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;37:801-870.
25. Basit A, Lacey L. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 2001;227:157-165.
26. Coffin M, Parr A, inventors. Glaxo Inc. Ranitidine solid dosage form. US patent 5 407 687. April 18, 1995.
27. Mendenhall W, Sincich T, eds. Multiple regression. In: A Second Course in Business Statistics, Regression Analysis. 3rd ed. San Francisco, CA: Dellen Publishing Co; 1989:141-226.